Immune-compromised people with HIV, APOE4 gene may have a compounded risk for Alzheimer's

22 February 2021

The finding appears online this month in the journal AIDS.

"We know that the hippocampus plays a critical role in memory and the caudate is a key region involved in HIV-associated neurocognitive disorders," said Xiong Jiang, Ph.D., an assistant professor at Georgetown who heads the Cognitive Neuroimaging Laboratory. "We wanted to understand whether HIV disease and APOE4 may concomitantly and/or interactively affect these areas of brain function."

The AIDS crisis began in mostly young men in the early 1980s, and by now nearly half of people living with HIV in the U.S. today are 50 or older. There have been significant advances in therapies for HIV that help account for the older survivors, including a combination antiretroviral therapy, or cART. This therapy stops HIV infection from progressing to full-blown AIDS in many people and transforms HIV-infection from a rapidly fatal illness to a chronic, manageable condition. Despite the advent of cART, people living with HIV can still develop neurological conditions known as HIV-associated neurocognitive disorders. Longevity now poses emerging additional risks related to other brain-related diseases, including Alzheimer's.

To try to better understand this risk, the researchers recruited 104 people with HIV from the Washington, DC, metropolitan area. To image areas of memory and other brain functions, the clinicians used resting-state functional MRI where no tasks or stimuli were given during the scan.

The investigators found that APOE4 was associated with reduced functional connectivity (the ability of two distinct areas of the brain to communicate) between the hippocampus and the caudate in people with HIV. This reduced functional
connectivity was associated with poorer memory function. Importantly, a history of severe immunosuppression led to further reduction in functional connectivity that contributed to reduced memory performance in APOE4 carriers, but not in APOE4 non-carriers. The investigators concluded that a history of severe immunosuppression may compound the effects of APOE4. They also found that executive function, primarily the ability to conduct everyday chores, was not impaired in these same people.

Most treatments in development for Alzheimer's are focusing on signal pathways related to the hippocampus and associated regions, where new memories are formed and where the earliest signs of the disease are seen. However, in people with HIV, this study suggests that in addition to the hippocampus, the regions they identified, such as the caudate, might need to be considered and included in a treatment plan.

"A helpful study would be to compare HIV-positive people ages 18 to 40 with those over age 70 to investigate whether, and how, age interacts with APOE4 and HIV disease in affecting brain function," said Jiang. "Also, we're exploring a possible therapeutic investigation that uses transcranial direct current stimulation. A constant electrical current is delivered via electrodes placed on the scalp that indirectly stimulates the caudate or hippocampus of people with HIV to try to lessen functional deterioration of memory."

**More information:** Yang, Fan Nilisa et al. Low CD4 nadir exacerbates the impacts of APOE ?4 on functional connectivity and memory in adults with HIV. *AIDS* February 05, 2021 [DOI: 10.1097/QAD.0000000000002840]

---

**Provided by Georgetown University Medical Center**
